ACDF Using Structural Allograft vs. Tritanium C


Allegheny Health Network (AHN)




Degenerative Disc Disease


Device: Tritanium C
Procedure: Structural allograft

Study type


Funder types



Stryker IIT

Details and patient eligibility


This is an observational, descriptive, prospective and retrospective data collection study. The purpose of this study is to observe radiographic outcomes of patients who will undergo anterior cervical discectomy and fusion (ACDF) utilizing Tritanium C (Stryker Spine). The rate of fusion success and adverse events will be compared retrospectively to patients who underwent instrumented ACDF utilizing structural allograft bone with plates.

Full description

Retrospective subjects will consist of 20 patients that received one or two level ACDF structural allograft with plates with autograft and/or allograft comprised of cancellous and /or corticocancellous bone chips. These subjects will be retrospectively reviewed for radiographic outcomes at 3, 6 and 12 months postoperatively, as well as adverse events and sensory and motor outcomes. If available, NDI and VAS questionnaires completed during baseline and post-op visits will be collected. Prospective subjects will consist of 20 patients who are receiving Tritanium C as standard of care. These subjects will be asked to complete NDI and VAS questionnaires at baseline and post-op visits. Radiographic outcomes, adverse events, sensory and motor neurological outcomes, as determined per standard of care will be collected at those same time points. The total number of subjects is N=40.


40 estimated patients




18 to 80 years old


No Healthy Volunteers

Inclusion criteria

  1. Males or females ≥18 years of age, ≤ 80 years of age
  2. Subject is skeletally mature
  3. Subject is diagnosed with degenerative disc disease (DDD) at one level or two contiguous levels from the C2 -T1 disc
  4. Subject has received six weeks of non-operative therapy i.e. injections, physical therapy, oral steroids
  5. Subject understands the conditions of enrollment and is willing to sign and date the Informed Consent (Prospective study)
  6. Subjects that will prospectively undergo one or two level anterior cervical discectomy and fusion with Tritanium C (Prospective study)
  7. Subjects that have previously undergone one or two level anterior cervical discectomy and fusion with either standard of care structural allograft bone (Retrospective study)

Exclusion criteria

Patients may not be enrolled in the study if any of the following exclusion criteria are present:

  1. Presence of an infection systemic or local
  2. Presence of marked local inflammation
  3. Subject has any abnormality present which affects the normal process of bone remodeling including, but not limited to, severe osteoporosis involving the spine, bone absorption, osteopenia, primary or metastatic tumors involving the spine, active infection at the site or certain metabolic disorders affecting osteogenesis
  4. Use of bone growth stimulator
  5. Subject has prior fusion at the levels to be treated
  6. Subject has any neuromuscular deficit
  7. Subject has any condition of senility, mental illness, or substance abuse
  8. Subject has any other medical or surgical condition which would preclude the potential benefit of spinal implant surgery in the judgement of the PI
  9. Subject has rapid joint disease, bone absorption, osteopenia, osteomalacia, and/or osteoporosis. Subject is pregnant or plans to become pregnant during the course of the study.
  10. BMI≥40 kg/m2
  11. Subject uses chronic corticosteroids
  12. Subjects with current active psychiatric diagnosis or a personality disorder likely to interfere with the study
  13. Subjects who smoke and do not plan to quit
  14. Mental or neuromuscular disorder which would create an unacceptable risk of fixation failure or complications in postoperative care
  15. Subject has any open wounds
  16. Subject has inadequate tissue coverage over the operative site
  17. Subject may be sensitive to titanium materials

Trial design

40 participants in 2 patient groups

20 patients that received one or two level ACDF structural allograft with plates with autograft and /or allograft comprised of cancellous and/or corticocancellous bone chips.
Procedure: Structural allograft
20 patients who are receiving Tritanium C as standard of care.
Device: Tritanium C

Trial contacts and locations



Central trial contact

Alexander Yu, MD; Nestor Tomycz, MD

Data sourced from

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems